At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Icosapent Ethyl and Prevention of Vascular Regenerative Cell Exhaustion Study
In Brief
A Phase 4 clinical trial evaluating Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] for Cardiovascular Diseases and 3 related conditions. Completed, enrolled 70 participants across 3 sites.
Detailed Summary
IPE-PREVENTION is a prospective, randomized, 3-month long, open-label study. A total of 70 individuals with elevated cardio-metabolic risk and heightened triglyceride levels, and who are on stable statin therapy will be randomized (1:1) to receive either icosapent ethyl (IPE) 2g BID or standard of care. It is hypothesized that assignment to IPE will lower progenitor cell depletion as well as limit progenitor cell dysfunction. This study may offer some molecular and cellular insights into the mechanisms underlying the cardiovascular benefits of IPE therapy reported in the REDUCE-IT trial.
Study Details
Timeline
Interventions
2 x 1g capsules BID as per REDUCE-IT